December 11, 2017

Morphotek and Rockefeller University Form a Sponsored Research Agreement to Study the Immunosuppressive Effects of the Tumor Shed Antigen CA125 and its Potential Impact in Future Patient Therapies
Read More

December 7, 2017

Morphotek to Present its Proprietary RESPECT Antibody-Drug Conjugate (ADC) Technology at the Upcoming Antibody Engineering & Therapeutics Conference in San Diego
Read More

December 4, 2017

Morphotek Announces Initiation of Phase 1 Study of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 in Solid Tumors with Folate Receptor Alpha Expression
Read More

News & Events > News Archive > 2017 News